The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
|Articles|August 1, 2016
- BioPharm International-08-01-2016
- Volume 29
- Issue 8
Sterile Bag Streamlines Environmental Monitoring Workflows
The IsoBag from MilliporeSigma is used for the convenient transfer of contact and settle plates to production isolators.
Advertisement
The IsoBag from MilliporeSigma is used for the convenient transfer of contact and settle plates to production isolators. The IsoBag offers a streamlined alternative for environmental monitoring and increases operation up-time by eliminating decontamination cycles. The bag allows for an uninterrupted workflow and is gamma-irradiated for immediate use. The IsoBag also includes sterile bags for safe transport of used plates.
Articles in this issue
about 10 years ago
Generating a Fully Processed Antibodyabout 10 years ago
Perfusion in the 21st Centuryabout 10 years ago
Protein Impurities Pose Challengesabout 10 years ago
All Buzz, No Biteabout 10 years ago
Analysis of Glycosylation in Biosimilarsabout 10 years ago
Quality Manufacturing Key to Stemming Drug Shortagesabout 10 years ago
Downstream Processing Continues to Worry CMOsabout 10 years ago
One Strategy for Updating an Aging Facilityabout 10 years ago
Integrating Single-Use Systems in Biopharma Manufacturingabout 10 years ago
The Flexibility of Small-Scale Single-Use Bioreactor SolutionsAdvertisement
Related to this article
Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.
A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease
3
Zymeworks Licenses DLL3-Targeted Trispecific T-Cell Engager ZW209 to Roche in Deal Worth Up to $813 Million
4
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
5